Latest Funding News

Epx Limited reports sustained operational improvement with four consecutive quarters of positive cash inflows and a 26% increase in customer receipts for the June 2025 quarter.

Gibb River Diamonds has commenced grade control drilling at its Neta Prospect in Western Australia, moving closer to potential mining operations pending regulatory approval.

Future Generation Australia has announced its tenth consecutive annual increase in fully franked interim dividends, driven by a strong 10.8% return on its investment portfolio over the past year.

Orange Minerals NL has raised $810,000 to fund exploration and due diligence on its new Tepa Gold Project acquisition in Ghana, while advancing promising Australian projects with notable assay results.

West Coast Silver has raised over $6 million through a share placement to accelerate exploration at its high-grade Elizabeth Hill silver project, signalling strong investor confidence and ambitious growth plans.

EQ Resources Limited highlighted its growing global footprint in tungsten mining at the 2025 Noosa Mining Conference, detailing production growth, reserve expansions, and strategic funding initiatives.

Catalyst Metals reported steady gold production in the June 2025 quarter, progressing development at its Trident project while completing key corporate transactions that strengthen its growth outlook.

Merchant House International has completed the sale of its American Merchant, Inc. assets, generating significant profits and setting the stage for winding up operations and voluntary delisting from the ASX.

InVert Graphite Limited has successfully raised $3.5 million and resumed ASX trading following key acquisitions and promising initial trench results at its Morogoro Graphite Project.

Novonix Limited reports significant progress in its synthetic graphite anode materials production, benefiting from new US tariffs on Chinese imports and strategic leadership appointments. The company also secures up to US$100 million in convertible debenture funding to support expansion plans.

NOVONIX has entered a multi-tranche funding agreement with Yorkville Advisors to raise up to US$100 million through convertible debentures, supporting its Riverside facility build-out and commercial production ramp-up.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.